Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.79+0.45%BTC$85,618.00-0.20%ETH$2,695.89-0.68%GOLD$4,191.90+0.84%OIL$89.82+0.44%
Smart Investors Daily
SID Premium
TE

NASDAQ · TECX

Tectonic Therapeutic, Inc.

Healthcare · Biotechnology

$23.11

Down-$0.20 (-0.84%)

Updated Oct 6, 2026, 5:54 PM

SID Score

2.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
364.22M
P/E ratio
-5.41
Dividend yield
0.00%
52-week range
$21.71 – $39.53
Volume
312.65K
Avg. volume
513.83K

Price performance · TECX

TECX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

TECX closed at $23.11 after 20 trading sessions, down 23.98% for the selected period.

Last close
$23.11
Period change
-23.98%
Period low
$22.54
Period high
$30.48
Daily close
View OHLC price history
TECX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$22.67$23.32$21.71$23.11312.65K
Oct 2, 2026$22.73$23.07$22.14$22.54253.43K
Oct 1, 2026$23.25$23.65$22.41$22.67343.51K
Sep 30, 2026$23.66$23.66$22.60$23.29251.63K
Sep 29, 2026$23.85$24.54$22.54$23.341.05M
Sep 28, 2026$23.54$23.9899$23.125$23.51234.84K
Sep 25, 2026$24.19$24.66$23.55$23.6797.05K
Sep 24, 2026$24.85$24.86$23.06$24.12214.41K
Sep 23, 2026$26.56$26.58$24.20$24.98207.42K
Sep 22, 2026$26.83$27.5799$26.21$26.50188.6K
Sep 21, 2026$27.35$27.35$26.31$26.63131.81K
Sep 18, 2026$27.30$27.59$26.38$27.00330.59K
Sep 17, 2026$28.15$28.71$27.105$27.21186.78K
Sep 16, 2026$28.50$29.23$27.68$27.91188.42K
Sep 15, 2026$29.71$30.015$27.95$28.51220.9K
Sep 14, 2026$29.39$30.73$29.38$29.71145K
Sep 11, 2026$29.03$29.395$28.5575$29.05154.98K
Sep 10, 2026$30.06$30.32$28.40$28.61252.39K
Sep 9, 2026$30.18$30.995$29.81$30.48133.37K
Sep 8, 2026$30.32$31.41$29.955$30.40116.58K

Latest TECX news

The latest Smart Investors Daily articles mentioning TECX.

Stock researchCompany · Overview

TECX research

Overview

Company profile and research snapshot.

Company profile

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TECX recent ratings
DateFirmRatingTarget
Aug 7, 2026Wells FargoOverweight—
May 26, 2026Raymond JamesStrong Buy—
Apr 14, 2026StifelBuy—
Jan 8, 2026Truist SecuritiesBuy—
Sep 3, 2025OppenheimerOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)

U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investigational New Drug (IND) application for the TX2100 Phase 1b clinical trial in HHT patients in the U.S.TX2100 Phase 1a clinical trial topline results demonstrated single ascending doses of TX2100 were generally safe and well-tolerated in healthy adult volunteersCompany plans to initiate an open-label TX2100 Phase 1b clinical trial in patients with hematologic-support dependent HHT by year-end 2026, and initiate a

Yahoo · Sep 10, 2026

Tectonic Therapeutic (TECX) Clears Two Trial Hurdles With Cash To Spare

On August 6, Tectonic Therapeutic (NASDAQ:TECX) reported second quarter results built around two clinical wins rather than sales figures, since this is a clinical stage biotech company with no products on the market yet. The headline news is that both of its lead programs hit their scheduled marks this year, and the company says it […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By